Back to today’s briefing

Story perspectives

ALZ-801 Trial Shows Promise in Slowing Alzheimer's Decline

10/31/2025

47 11

Summary

Story summary

ALZ-801 may slow memory loss and brain shrinkage in early Alzheimer's patients with APOE4, per a phase 3 trial by Alzheon, Inc.
The trial enrolled 325 participants aged 50–80 and showed a 50% memory decline reduction in mild cognitive impairment.
ALZ-801 appears to prevent amyloid plaque formation without brain swelling.
The study had limitations related to duration and its focus on a specific genetic group.
Further research is needed.

1 of 1

Story summary

ALZ-801 may slow memory loss and brain shrinkage in early Alzheimer's patients with APOE4, per a phase 3 trial by Alzheon, Inc.
The trial enrolled 325 participants aged 50–80 and showed a 50% memory decline reduction in mild cognitive impairment.
ALZ-801 appears to prevent amyloid plaque formation without brain swelling.
The study had limitations related to duration and its focus on a specific genetic group.
Further research is needed.